Preoperative Pregabalin and the Cp50 for Skin Incision During Target-Controlled Propofol Infusion: A Randomized,...

Area of Science:

• Anesthesiology
• Pharmacology

Background:

• Propofol's potency is defined by its Cp50, the plasma concentration suppressing motor response in 50% of patients.
• Concurrent medications can alter propofol's Cp50.
• Pregabalin's effect on propofol-based anesthesia requires further investigation.

Purpose of the Study:

• To evaluate the impact of preoperative pregabalin on the propofol Cp50.
• To determine if pregabalin alters the anesthetic requirements of propofol.

Main Methods:

• A placebo-controlled, double-blind trial involving 80 female patients undergoing breast surgery.
• Patients received either placebo or 300 mg pregabalin 2 hours before anesthesia.
• Propofol was the sole anesthetic agent, administered via target-controlled infusion (TCI); Cp50 was determined via logistic regression.

Main Results:

• Pregabalin significantly reduced propofol Cp50 by 44% (9.4 μg/mL) compared to placebo (16.9 μg/mL).
• The pregabalin group showed significantly lower postoperative opioid consumption and pain scores.

Conclusions:

• Pretreatment with 300 mg pregabalin significantly decreases propofol's Cp50.
• Lower target effect-site concentrations of propofol may be sufficient with pregabalin premedication.
• Pregabalin may reduce postoperative pain and opioid requirements.